Zenas BioPharma Appoints Lisa Von Moltke, M.D. as Head of Research and Development and Chief Medical Officer
Position
Head of Research and Development
Company
Zenas BioPharma
WalthamBiotechnologyHealth CareTherapeuticsDescription
Zenas BioPharma, Inc announced the appointment of Lisa von Moltke, MD, as its new Head of Research and Development and Chief Medical Officer. Dr von Moltke brings over three decades of experience in drug development, with expertise in autoimmune diseases, to the Zenas leadership team. Her immediate focus will be on advancing Zenas’s lead product candidate, obexelimab, through critical Phase 2 and Phase 3 clinical trials for autoimmune diseases such as IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Quick answer
Zenas BioPharma Appoints Lisa Von Moltke, M.D. as Head of Research and Development and Chief Medical Officer (March 19, 2025). Zenas BioPharma is based in Waltham, Massachusetts, United States.
- Who is the new Head of Research and Development at Zenas BioPharma?
- Zenas BioPharma named Lisa von Moltke Head of Research and Development, announced March 19, 2025.
- What did Zenas BioPharma announce on March 19, 2025?
- Zenas BioPharma, Inc announced the appointment of Lisa von Moltke, MD, as its new Head of Research and Development and Chief Medical Officer. Dr von Moltke brings over three decades of experience in drug development, with expertise in autoimmune diseases, to the Zenas leadership team.
- What does Zenas BioPharma do?
- Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world.
- Where is Zenas BioPharma based?
- Zenas BioPharma is based in Waltham, Massachusetts, United States.
- Which similar companies made leadership changes around the same time?
- Hyku Biosciences (March 19, 2025), Bristol Myers Squibb (March 20, 2025), Immuneering (March 20, 2025) and Nanoscope Therapeutics (March 20, 2025) also announced leadership changes within 45 days of Zenas BioPharma.
Source: Fundz verified event record.
Other recent leadership changes in Therapeutics and Biotechnology
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Hyku Biosciences Names Keith Wilcoxen as Chief Scientific Officer (March 19, 2025)
- Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia and Gulf Countries (March 20, 2025)
- Igor Matushansky, MD, PhD, Joins Immuneering as Chief Medical Officer (March 20, 2025)
- Nanoscope Therapeutics Appoints Ademola Daramola as Vice President, Quality and Compliance (March 20, 2025)
- Dyne Therapeutics Appoints Erick J. Lucera as Chief Financial Officer (March 20, 2025)
- Exubrion Therapeutics Appoints Jennifer Kirk as Chief Executive Officer (March 18, 2025)
Who to call at Zenas BioPharma, and when
A new leader at Zenas BioPharma brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Zenas BioPharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Zenas BioPharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Zenas BioPharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Zenas BioPharma changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Zenas BioPharma changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.